Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss
Open Access
- 14 March 2025
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (6) , 1978
Abstract
The last two decades have proffered many remarkable choices in managing type 1 and type 2 diabetes mellitus. Leading the list are glucagon-like peptide-1 receptor agonists (GLP1RAs), the first of which, exenatide, was approved by the FDA in 2005. Two other major classes of drugs have also entered the market: dipeptidyl peptidase-4 (DPP-4) inhibitors, commonly known as gliptins and approved in 2006, and sodium–glucose cotransporter-2 (SGLT-2) inhibitors, with the first approval occurring in 2013. These drugs have revolutionized the treatment of diabetes. Additionally, on the horizon, the once-weekly basal insulin analog insulin icodec and the once-weekly combination of insulin icodec and semaglutide are expected to be available in the future. Beyond glycemic control, GLP1RAs have exhibited benefits in conditions associated with diabetes, including hypertension, dyslipidemia, non-alcoholic steatohepatitis, as well as in neurodegenerative diseases such as Alzheimer’s disease. Additionally, emerging research suggests potential roles in certain types of cancer, infertility, and associative learning. Major cardiovascular events seem to be lower in patients on GLP1RAs. While some evidence is robust, other findings remain tenuous. It is important that clinicians are familiar with current research in order to provide optimal evidence-based care to patients. In the not-too-distant future, there may be a case to prescribe these drugs for benefits outside diabetes.Keywords
This publication has 118 references indexed in Scilit:
- Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 DiabetesJAMA Network Open, 2024
- GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/ObesityJAMA Oncology, 2024
- Lifestyle changes in women with polycystic ovary syndromeCochrane Database of Systematic Reviews, 2019
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver DiseasesHepatology, 2017
- Extrahepatic complications of nonalcoholic fatty liver diseaseHepatology, 2014
- Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout miceDiabetologia, 2011
- The potential for bias in reporting of industry‐sponsored clinical trialsPharmaceutical Statistics, 2011
- Insulin Resistance and Alzheimer-like Reductions in Regional Cerebral Glucose Metabolism for Cognitively Normal Adults With Prediabetes or Early Type 2 DiabetesArchives of Neurology, 2011
- The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and miceDiabetologia, 2009
- SynucleinopathiesArchives of Neurology, 2001